Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Sophie-Luise Mersiowsky, Gabriele Ihorst, Valerie Arnold, Michael J. Müller, Olga Grishina, Claudia Schmoor, Hartmut Bertz, Barbara Deschler-Baier, Ulrich Germing, Björn Hackanson, Michael Lübbert

Blood (2024) 144 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2024-203583

Published: 2024

Journal Articles

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

David Alber, Christoph Rummelt, Tim Strüßmann, Andrés Rettig, Valeria Shlyakhto, Paul La Rosée, Martin Henkes, Elizaveta Bubnova, Tobias Ma, Johanna Thomas, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Heiko Becker, Justus Duyster, Ralph Wäsch, Jürgen Finke, Michael Lübbert

Blood (2023) 142 (Supplement 1): 7091.

https://doi.org/10.1182/blood-2023-187581

Published: 2023

Journal Articles

Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure

Miriam Mozaffari Jovein, Gabriele Ihorst, Jesus Duque Afonso, Ralph Wäsch, Claudia Wehr, Hartmut Bertz, Justus Duyster, Robert Zeiser, Jürgen Finke, Florian Scherer

Blood (2023) 142 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2023-179103

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Reduced-Intensity Conditioning Prior Autologous Stem Cell Transplantion in Elderly DLBCL Patients

Tim Struessmann, Philipp Hermes, Gabriele Ihorst, Jürgen Finke, Monika Engelhardt, Reinhard Marks

Blood (2022) 140 (Supplement 1): 9523–9524.

https://doi.org/10.1182/blood-2022-159492

Published: 2022

Journal Articles

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Blood (2022) 140 (Supplement 1): 1773–1774.

https://doi.org/10.1182/blood-2022-162157

Published: 2022

Journal Articles

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Christine Greil, Monika Engelhardt, MD, Gabriele Ihorst, Hartmut Bertz, MD, Reinhard Marks, MD, Robert Zeiser, MD, Justus Duyster, MD, Jürgen Finke, MD, Ralph Wäsch, MD

Blood (2019) 134 (Supplement_1): 4597.

https://doi.org/10.1182/blood-2019-130146

Published: 2019

Journal Articles

The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability

Katja Schoeller, Gabriele Ihorst, Sophia Scheubeck, Max Holler, Sandra M. Woerner, Heike Reinhardt, Stefan P. Müller, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 3474.

https://doi.org/10.1182/blood-2019-127030

Published: 2019

Journal Articles

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Blood (2018) 132 (Supplement 1): 720.

https://doi.org/10.1182/blood-2018-99-115974

Published: 2018

Journal Articles

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Sophia Scheubeck, Gabriele Ihorst, Sandra M. Dold, MSc, Katja Schoeller, Martin Boeker, PD, Stefan J. Müller, PharmD, Johannes M. Waldschmidt, MD, Rebeka Javorniczky, MD, Alessandra Larocca, Margrit Ott, MD, Hermann Einsele, Justus Duyster, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 3436.

https://doi.org/10.1182/blood.V130.Suppl_1.3436.3436

Published: 2017

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma — Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective 'Deutsche Studiengruppe Multiples Myelom' (DSMM) Analysis

Giulia Graziani, Georg W. Herget, Gabriele Ihorst, Henning Schäfer, Jakob Neubauer, Annette M. May, Justus Duyster, Hermann Einsele, Ralph Wäsch, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 4710.

https://doi.org/10.1182/blood.V130.Suppl_1.4710.4710

Published: 2017

Journal Articles

Deutsche Studiengruppe Multiples Myelom (DSMM) Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 MM Patients with Extensive, Complete and Repeated and Long-Term Follow-up

Maximilian Schinke, BSc, Gabriele Ihorst, Inga Promny, MD, Hermann Einsele, Justus Duyster, Ralph Wäsch, MD, Martin Schumacher, PhD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 2163.

https://doi.org/10.1182/blood.V130.Suppl_1.2163.2163

Published: 2017

Journal Articles

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Stefan J. Müller, PharmD, Dagmar Wider, Andreas R. Thomsen, MD, Marie Follo, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, Sandra M. Dold, MSc, Julia Felthaus, Johanna Senger, PhD, Julia Schüler, DVM, Justus Duyster, Abdel Kareem Azab, PhD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 1793.

https://doi.org/10.1182/blood.V130.Suppl_1.1793.1793

Published: 2017

Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Blood (2017) 130 (Supplement 1): 4261.

https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261

Published: 2017

Journal Articles

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Maximilian Schinke, Inga Promny, MD, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Roland H. Mertelsmann, MD PhD, Justus Duyster, MD, Ralph M. Waesch, MD, Martin Schumacher, PhD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5953.

https://doi.org/10.1182/blood.V128.22.5953.5953

Published: 2016

Journal Articles

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Sophia Scheubeck, Sandra Maria Dold, M. Sc., Gabriele Ihorst, PhD, Alexander Zober, MD, Stefan J. Müller, Dipl.-Pharm., Christian Langer, MD, Wolfram Pönisch, Lars-Olof Mügge, MD, Stefan Knop, MD, Justus Duyster, MD, Martin Schumacher, PhD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5627.

https://doi.org/10.1182/blood.V128.22.5627.5627

Published: 2016

Journal Articles

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Rainer Claus, MD, Gabriele Ihorst, PhD, Philipp Sander, Ljudmila Bogatyreva, Heiko Becker, MD, Pierre W Wijermans, MD, Stefan Suciu, Emmanuel Bissé, MD PhD, Michael Lübbert, MD

Blood (2016) 128 (22): 3175.

https://doi.org/10.1182/blood.V128.22.3175.3175

Published: 2016

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

Benjamin Kasenda, MD PhD, Gabriele Ihorst, PhD, Heidi Fricker, Elke Valk, PhD, Elisabeth Schorb, MD, Kristina Fritsch, MD, Jürgen Finke, Gerald Illerhaus, MD

Blood (2016) 128 (22): 5385.

https://doi.org/10.1182/blood.V128.22.5385.5385

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

NARROW

A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Reduced-Intensity Conditioning Prior Autologous Stem Cell Transplantion in Elderly DLBCL Patients

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma — Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective 'Deutsche Studiengruppe Multiples Myelom' (DSMM) Analysis

Deutsche Studiengruppe Multiples Myelom (DSMM) Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 MM Patients with Extensive, Complete and Repeated and Long-Term Follow-up

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only